RXi Pharmaceuticals
Corporation RXII, a biotechnology company focused on discovering,
developing and commercializing innovative therapies addressing major unmet
medical needs using RNA-targeted technologies, today announced that a review
of the first two enrolled patients' clinical photographs in the first Phase 2a
clinical trial (RXI-109-1301), indicate that treatment with the Company's lead
clinical candidate, RXI-109, may be effective in suppressing recurrence of
hypertrophic scars at the 3-month time point. Patients will continue to be
monitored through 9 months to evaluate if this outcome persists over time.
On September 10^th of this year, the Company announced that based on early
1-month observations, the dosing regimen in these trials can be fine-tuned,
allowing the Company to more rapidly move forward with treatment optimization
for the prevention of scarring after surgery. Today's presentation will
provide 3-month photographs from the first two patients enrolled in study
RXI-109-1301 that indicate treatment with RXI-109 shows a clinical benefit.
The safety information in this ongoing study to date, continues to confirm
that RXI-109 is well tolerated with no overt systemic side effects. Local
effects are mild and similar to those seen in the Company's prior Phase 1
clinical trials (erythema, occasional, transient burning or stinging
sensation). Complete 3-month results from this trial are expected to be
available in Q1 2015.
"We are encouraged by the preliminary results in this trial," said Dr. Geert
Cauwenbergh, President and CEO of RXi Pharmaceuticals. "To date, our Phase 2a
studies are providing us with exactly the information for which such studies
are intended, early information on dosing requirements and observation of a
clinical effect of the drug. Having this information in hand now should save
money and time going forward in our clinical development as we will
incorporate these learnings into future clinical protocols."
The presentation will be webcast today, Tuesday, October 7, 2014 at 10:00 a.m.
PST, at the 13^th Annual BIO Investor Forum. The webcast will be available on
the "Investors" section of the Company's website, www.rxipharma.com.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in